The short version of gastric juice protein fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-03-23 and is reviewed periodically as new material appears.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
Peptides are susceptible to hydrolysis, oxidation, and aggregation, and BPC-157 is no exception. The lyophilized powder form is generally more stable than a solution because residual moisture is low and molecular mobility is reduced. Once dissolved, the peptide is exposed to water, oxygen, and trace metal ions that accelerate degradation. Light exposure and repeated freeze-thaw cycles are also commonly cited as sources of loss. These general principles guide most handling recommendations found in supplier documentation.
Standard practice for the solid form is storage at minus twenty degrees Celsius or colder, kept dry and away from light. Containers are usually sealed with a desiccant to limit moisture uptake. Reconstituted solutions are typically held at two to eight degrees Celsius and used within a short window, because potency can decline over days to weeks depending on the buffer and concentration. Freezing an already dissolved sample may help, though repeated thawing is discouraged. Specific shelf-life claims vary between suppliers and are rarely supported by published stability studies.
| Property | Value | Notes |
|---|---|---|
| Molar mass | Approximately 1419.5 g/mol | Calculated from the reported 15-residue sequence |
| Molecular formula | C62H98N16O22 | Based on the same sequence |
| Appearance | White to off-white powder | Typical of a lyophilized preparation |
| Solubility class | Freely soluble in water | Also dissolves in saline solutions |
| Typical storage temperature | Minus 20 degrees Celsius, dry | Refrigeration advised after reconstitution |
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
It has the potential to transform not only the retailing landscape but also the nation's ailing infrastructure., A Wall Street Journal article claims that fresh investments in Indian organised retail will generate 10 million new jobs between 2012 and 2014, and about five to six million of them in logistics alone; even though the retail market is being opened to just 53 cities out of about 8000 towns and cities in India.
The Maya civilization emerged at least three millennia ago in the lowland area of the Yucatán Peninsula and the highlands to the south, in the area of present-day southeastern Mexico, Belize, Guatemala, and western Honduras. Many aspects of this culture persist in the area, despite nearly 500 years of European domination. Before about 2500 BC, some hunting and foraging bands settled in small farming villages; they domesticated crops such as corn, beans, squash, and chilli peppers. A profusion of languages and subcultures developed within the Maya core culture. Between about 2500 BCE and 250 AD, the basic institutions of Maya civilization emerged.
The Komodo dragon is classified by the IUCN as Endangered and is listed on the IUCN Red List. The species' sensitivity to natural and human-made threats has long been recognized by conservationists, zoological societies, and the Indonesian government. Komodo National Park was founded in 1980 to protect Komodo dragon populations on islands including Komodo, Rinca, and Padar. Later, the Wae Wuul and Wolo Tado Reserves were opened on Flores to aid Komodo dragon conservation. Volcanic activity, earthquakes, loss of habitat, fire, tourism, loss of prey due to poaching, and illegal poaching of the dragons themselves have all contributed to the vulnerable status of the Komodo dragon. A major future threat to the species is climate change via both aridification and sea level rise, which can affect the low-lying habitats and valleys that the Komodo dragon depends on, as Komodo dragons do not range into the higher-altitude regions of the islands they inhabit. Based on projections, climate change will lead to a decline in suitable habitat of 8.4%, 30.2%, or 71% by 2050 depending on the climate change scenario. Without effective conservation actions, populations on Flores are extirpated in all scenarios, while in the more extreme scenarios, only the populations on Komodo and Rinca persist in highly reduced numbers. Rapid climate change mitigation is crucial for conserving the species in the wild. Other scientists have disputed the conclusions about the effects of climate change on Komodo dragon populations.
Sources: en.wikipedia.org
== Ownership == In 2011, CCMP Capital acquired 80% of the firm for US$285 million. Three years later, in February 2014, CCMP auctioned their 80% stake; the winner was won by Cinven, who paid US$900 million. In August 2017, Medpace went became a publicly traded company with its initial public offering, selling 8,050,000 shares of common stock.
=== Ron Hites Award: for an exemplary paper published in the previous two volumes of the Journal of the American Society for Mass Spectrometry (since 2009) === 2022 Elyssia Gallagher 2019 Julia Laskin 2009 Alison Ashcroft
== Interactions == A number of drugs add to the low blood pressure caused by nitrovasodilators: for example, other vasodilators, antihypertensive drugs, tricyclic antidepressants, antipsychotics, general anaesthetics, as well as ethanol. Combination with PDE5 inhibitors, including sildenafil (Viagra), is contraindicated because potentially life-threatening hypotension may occur. Nitrates increase the bioavailability of dihydroergotamine (DHE). High DHE levels may result in coronary spasms in patients with coronary disease. This interaction is not described for non-nitrate nitrovasodilators.
Sources: en.wikipedia.org
Korolev was buoyed by the first successful launches of the R-7 rocket in August and September, which paved the way for the launch of Sputnik 1. Word came that the US was planning to announce a major breakthrough at an International Geophysical Year conference at the National Academy of Sciences in Washington D.C., with a paper titled "Satellite Over the Planet", on October 6, 1957. Korolev anticipated that von Braun might launch a Jupiter-C with a satellite payload on or around October 4 or 5, in conjunction with the paper. He hastened the launch, moving it to October 4. The launch vehicle for PS-1 was a modified R-7 – vehicle 8K71PS number M1-PS – without much of the test equipment and radio gear that was present in the previous launches. It arrived at the Soviet missile base Tyura-Tam in September and was prepared for its mission at launch site number one. The first launch took place on Friday, October 4, 1957, at exactly 10:28:34 pm Moscow time, with the R-7 and the now named Sputnik 1 satellite lifting off the launch pad and placing the artificial "moon" into an orbit a few minutes later. This "fellow traveler", as the name is translated in English, was a small, beeping ball, less than two feet in diameter and weighing less than 200 pounds. But the celebrations were muted at the launch control center until the down-range far east tracking station at Kamchatka received the first distinctive beep ... beep ... beep sounds from Sputnik 1's radio transmitters, indicating that it was on its way to completing its first orbit.
Plants that cause illness or death after consuming them are referred to as poisonous plants. The toxins in poisonous plants affect herbivores, and deter them from consuming the plants. Plants cannot move to escape their predators, so they must have other means of protecting themselves from herbivorous animals. Some plants have physical defenses such as thorns, spines and prickles, but by far the most common type of protection is chemical. Over millennia, through the process of natural selection, plants have evolved the means to produce a vast and complicated array of chemical compounds to deter herbivores. Tannin, for example, is a defensive compound that emerged relatively early in the evolutionary history of plants, while more complex molecules such as polyacetylenes are found in younger groups of plants such as the Asterales. Many of the known plant defense compounds primarily defend against consumption by insects, though other animals, including humans, that consume such plants may also experience negative effects, ranging from mild discomfort to death. Many of these poisonous compounds also have important medicinal benefits. The varieties of phytochemical defenses in plants are so numerous that many questions about them remain unanswered, including:
In computational biology, protein pKa calculations are used to estimate the pKa values of amino acids as they exist within proteins. These calculations complement the pKa values reported for amino acids in their free state, and are used frequently within the fields of molecular modeling, structural bioinformatics, and computational biology.
== Early life and education == Shiva Ayyadurai was born Vellayappa Ayyadurai Shiva in 1963, in Bombay (now Mumbai), India. He grew up in the Muhavur village in Rajapalayam, Tamil Nadu. At the age of seven, he left with his family to live in the United States. He was raised in Livingston, New Jersey. In 1978, as a 14-year-old high school student, Ayyadurai attended a summer program at the Courant Institute of Mathematical Sciences of New York University (NYU) to study computer programming. While a student at Livingston High School in New Jersey, Ayyadurai volunteered at the University of Medicine and Dentistry of New Jersey (UMDNJ) where his mother worked. While there Leslie Michelson asked him to set up an electronic messaging system for 100 users at the medical school. In 1982, he registered the copyright for the source code and user documentation of the FORTRAN program called EMAIL. Ayyadurai's undergraduate degree from MIT was in electrical engineering and computer science; he took a master's degree in visual studies from the MIT Media Laboratory on scientific visualization; concurrently, he completed another master's degree in mechanical engineering, also from MIT; and in 2007, he obtained a PhD in biological engineering from MIT in systems biology, with his thesis focusing on modeling the whole cell by integrating molecular pathway models. In 2007, he was awarded a Fulbright U.S. Student Program grant to study the integration of Siddha, a system of traditional medicine developed in South India, with modern systems biology.
Sources: en.wikipedia.org
It does not occur in the form that is supplied commercially. Its sequence matches a fragment of a larger gastric protein, and the research material is produced synthetically in a laboratory. The fragment described in the early literature is generally the same synthetic pentadecapeptide.
It marks the position of the sequence inside the original protein. The label traces back to early work fractionating gastric juice and describing a body protection compound. The figure does not refer to molecular weight or to the count of amino acids.
No. The sequence has no cysteine residues, so disulfide bridges cannot form. That feature makes it easier to handle than many small proteins that depend on multiple cysteines for structure.
Reversed-phase HPLC separates the sample into peaks, and the main peak is expressed as a percentage of total peak area. Mass spectrometry is then used to confirm that the molecular mass matches the expected value.